Innovative therapies for inflammatory diseases and cancer
The immune system is an extraordinary network that protects our bodies from a wide range of threats. To keep us healthy, it must strike a delicate balance: mounting strong responses against infections or cancer while avoiding excessive activation that can lead to harmful inflammation and chronic disease.
Our research group is dedicated to understanding how this balance is achieved and how it can be therapeutically improved. We investigate the fundamental mechanisms that shape immune responses and explore pharmacological strategies to enhance treatments for inflammatory diseases and cancer. To do so, we combine cellular assays and preclinical models, using state‑of‑the‑art techniques to deeply characterize immune cell phenotypes and functions.
Because the immune system is remarkably complex, our projects span a wide scientific landscape. We study the roles of diverse immune cells — including dendritic cells, macrophages, neutrophils, and eosinophils — in initiating, sustaining, and regulating inflammation. We also specialize in cancer immunopharmacology, examining how immunomodulatory molecules such as gasotransmitters influence the immune response against cancer. A particular focus of our work is cellular metabolism: how metabolic pathways in both cancer cells and immune cells shape their interactions, and how metabolic interventions can improve therapeutic outcomes.
Across all these efforts, our goal is clear: to bridge fundamental immunology with clinical application. By uncovering new biological insights and identifying promising pharmacological targets, we aim to drive the development of innovative therapies for inflammatory diseases and cancer.
